Total Funding
72
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
106660
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.
Acquired by 
Kalaris Therapeutics
Ann Leen: Co-Founder & Chief Scientific Officer- Diana Brainard: Chief Executive OfficerPast Role: Gilead Sciences, Senior Vice President, Virology Therapeutic Area Head
About the Company
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.
Women Founded
